Table 1.

Patient characteristics

		N = 25
		N	(%)
Age (years)
	Median	51
	Range	31–72
Preoperative serum CA-125 level (U/ml)*
	Median	79.6
	Range	18.9–428.5
ECOG performance status
	0	16	64
	1	9	36
FIGO stage
	I A	4	16
	I C	7	28
	II B	2	8
	III A	1	4
	III C	10	40
	IV A	1	4
Primary tumor site
	Ovary	21	84
	Peritoneum	3	12
	Fallopian tube	1	4
Histology
	High-grade serous carcinoma	12	48
	Endometrioid carcinoma	5	20
	Clear cell carcinoma	7	28
	Others**	1	4
Supra-renal PAN enlargement on CT***
	Yes	2	8
	No	23	92
Ascites at laparotomy
	Yes	11	44
	No	14	56
Timing of surgery
	PDS or staging	15	60
	NAC-IDS***	10	40
Operative procedures
	TH+BSO	25	100
	Omentectomy	25	100
	Pelvic lymphadenectomy	25	100
	Para-aortic lymphadenectomy	25	100
	Pelvic peritoneum stripping	10	40
	Abdominal peritoneum stripping	11	44
	Recto-sigmoidectomy/anastomosis	1	4
	Large bowel resection	1	4
	Diaphragm stripping/resection	8	32
	Splenectomy	1	4
	Liver resection	1	4
	Small bowel resection	1	4
Residual tumors
	No macroscopic residual tumor	20	80
	Smaller than 1 cm in diameter	5	20
UICC TNM
	pT1	12	48
	pT2	2	8
	pT3 or ypT3	11	44
No. of dissected lymph nodes
PLN
	Median	26
	Range	14–55
Infra-renal PAN
	Median	21
	Range	12–36
Supra-renal PAN
	Median	5
	Range	2–10

Abbreviations: CA-125 cancer antigen 125, NAC neoadjuvant chemotherapy, IDS interval debulking surgery, ECOG Eastern Cooperative Oncology Group, FIGO International Federation of Gynecology and Obstetrics, TH total hysterectomy, BSO bilateral salpingo-oophorectomy, UICC Union for International Cancer Control, PLN pelvic lymph nodes, PAN para-aortic lymph nodes

*Including data obtained just before IDS

**Serous carcinoma + endometrioid carcinoma

***Enlargement of supra-renal PAN was defined as at least one node ≥ 1 cm on CT before the start of treatment

***Debulking surgery was performed after 3–4 cycles of chemotherapy (platinum + taxane + bevacizumab)